Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock

医学 左旋西孟旦 心源性休克 断奶 内科学 心脏病学 休克(循环) 体外膜肺氧合 麻醉 梅德林 重症监护医学 循环系统
作者
Alain Combes,Ouriel Saura,Nicolas Nesseler,Saïd Lebbah,Bertrand Rozec,Bruno Lévy,Jean-Luc Fellahi,Antoine Beurton,Simon Meslin,Philippe Gaudard,Adrien Bouglé,André Vincentelli,Romain Sonneville,Guillaume Lebreton,David Lévy,Alexandre Ouattara,Florence Tubach,LEVOECMO Trial Group and the International ECMO Network (ECMONet),Juliette Chommeloux,Grégoire Del Marmol
出处
期刊:JAMA [American Medical Association]
卷期号:335 (1): 60-60 被引量:4
标识
DOI:10.1001/jama.2025.19843
摘要

Importance: Levosimendan may facilitate weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) and improve survival, but supporting evidence remains limited. Objective: To assess whether early administration of levosimendan reduces the time to successful VA-ECMO weaning in patients with severe but potentially reversible cardiogenic shock. Design, Setting, and Participants: Randomized, double-blind, placebo-controlled trial conducted across 11 intensive care units (ICUs) in France. Between August 27, 2021, and September 10, 2024, 205 adult patients with acute cardiogenic shock who had started VA-ECMO in the preceding 48 hours were enrolled. Final follow-up was completed on November 10, 2024. Interventions: Patients were randomized in a 1:1 ratio to receive levosimendan, 0.15 μg/kg per minute, to be increased to 0.20 μg/kg per minute after 2 hours (n = 101), or placebo (n = 104). Main Outcomes and Measures: The primary outcome was time to successful ECMO weaning within 30 days following randomization. Secondary outcomes included ECMO-, mechanical ventilation-, and organ failure-free days, ICU and hospital lengths of stay, serious adverse events, and all-cause 30- and 60-day mortality. Results: Among the 205 randomized patients (median age, 58 [IQR, 50-67] years; 149 [72.7%] male), main cardiogenic shock etiologies were postcardiotomy (79 [38.5%]), acute myocardial infarction (56 [27.3%]), and myocarditis (28 [13.7%]). Treatment dose was increased to 0.20 ± 0.01 μg/kg per minute in 93% of patients receiving levosimendan and in 96% of those receiving placebo. Within 30 days, 69 of 101 patients (68.3%) had a successful ECMO weaning in the levosimendan group compared with 71 of 104 (68.3%) in the placebo group (risk difference, 0.0% [95% CI, -12.8% to 12.7%]; subdistribution hazard ratio, 1.02 [95% CI, 0.74-1.39]; P = .92). In the levosimendan and placebo groups, respectively, median ECMO duration (5 [IQR, 4-7] days vs 6 [IQR, 4-11] days; P = .53), mean ICU length of stay (18 [SD, 15] days vs 19 [SD, 15] days; P = .42), and 60-day mortality (27.7% vs 25.0%; risk difference, 2.7% [95% CI, -9.0% to 15.3%]; P = .78) did not differ significantly. Ventricular arrhythmias occurred more frequently with levosimendan (18 [17.8%] vs 9 [8.7%]; absolute risk difference, 9.2% [95% CI, 0.4%-18.1%]). Conclusions and Relevance: Among patients with severe but potentially reversible cardiogenic shock supported by VA-ECMO, early levosimendan administration did not significantly reduce the time to successful weaning of ECMO compared with placebo. Trial Registration: ClinicalTrials.gov Identifier: NCT04728932.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
幸运曲奇完成签到,获得积分10
1秒前
Zz发布了新的文献求助10
1秒前
麦克尔发布了新的文献求助10
1秒前
无限的丸子曾完成签到 ,获得积分10
2秒前
3秒前
迷路月光发布了新的文献求助10
3秒前
Husile发布了新的文献求助10
6秒前
延娜完成签到,获得积分10
6秒前
潮哦你完成签到,获得积分10
7秒前
文静的香烟完成签到,获得积分10
7秒前
online1881发布了新的文献求助30
7秒前
123发布了新的文献求助10
9秒前
JK0728完成签到,获得积分10
9秒前
可爱的函函的应助被zxy采纳,获得10
12秒前
14秒前
Oasis完成签到,获得积分10
14秒前
15秒前
积极镜子完成签到 ,获得积分10
16秒前
BAITUOBT完成签到,获得积分10
17秒前
17秒前
wirfish发布了新的文献求助10
18秒前
online1881完成签到,获得积分10
18秒前
18秒前
Eric发布了新的文献求助10
20秒前
坚强孤容发布了新的文献求助10
20秒前
21秒前
传奇3的应助被阔达的冰露采纳,获得10
21秒前
22秒前
22秒前
24秒前
李健的应助被科研通管家采纳,获得10
25秒前
领导范儿的应助被科研通管家采纳,获得10
25秒前
英姑的应助被科研通管家采纳,获得30
25秒前
25秒前
syvshc的应助被科研通管家采纳,获得30
25秒前
CipherSage的应助被科研通管家采纳,获得10
25秒前
深情安青的应助被科研通管家采纳,获得10
25秒前
25秒前
26秒前
爱听歌的盼柳完成签到,获得积分10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186734
求助须知:如何正确求助?哪些是违规求助? 9575007
关于积分的说明 21839114
捐赠科研通 7784289
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559206
邀请新用户注册赠送积分活动 2481611